Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action

Trends in Pharmacological Sciences

Volumn 30, Issue 7, 2009, Pages 356-362

  Jefferis, Royston ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CERTOLIZUMAB PEGOL; CETUXIMAB; COMPLEMENT COMPONENT C1Q; FC RECEPTOR; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G4; INFLIXIMAB; PANITUMUMAB; RECOMBINANT ANTIBODY; RECOMBINANT IMMUNOGLOBULIN G ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG;

ANAPHYLAXIS; ANTIBODY COMBINING SITE; ANTIGEN ANTIBODY COMPLEX; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BINDING AFFINITY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CROHN DISEASE; DISULFIDE BOND; DRUG CHOICE; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG STRUCTURE; DRUG TARGETING; DRUG TRANSPORT; GLYCOSYLATION; HUMAN; HYPERSENSITIVITY REACTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; TARGET CELL DESTRUCTION;

ANIMALS; ANTIBODIES; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN G; NEOPLASMS; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 67649394336     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2009.04.007     Document Type: Review

References (56)

1. Carter P.J. Potent antibody therapeutics by design. Nat. Rev. Immunol. 6 (2006) 343-357
2. Moutel S., and Perez F. Antibodies - Europe. Engineering the next generation of antibodies. Biotechnol. J. 3 (2008) 298-300
3. Reichert J.M., and Valge-Archer V.E. Development trends for monoclonal antibody cancer therapeutics. Nat. Rev. Drug Discov. 6 (2007) 349-356
4. Burton D.R., and Woof J.M. Human antibody effector function. Adv. Immunol. 51 (1992) 1-84
5. Jefferis R. Antibody therapeutics: isotype and glycoform selection. Expert Opin. Biol. Ther. 7 (2007) 1401-1413
6. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat. Rev. Drug Discov. 8 (2009) 226-234
7. Niwa R., et al. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. J. Immunol. Methods 306 (2005) 151-160
8. Holland M., et al. Anti-neutrophil cytoplasm antibody IgG subclasses in Wegener's granulomatosis: A possible pathogenic role for the IgG4 subclass. Clin. Exp. Immunol. 138 (2004) 183-192
9. van der Neut Kolfschoten M., et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 317 (2007) 1554-1557
10. Stebbings R., et al. 'Cytokine storm' in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J. Immunol. 179 (2007) 3325-3331
11. Liu Y.D., et al. Human IgG2 antibody disulfide rearrangement in vivo. J. Biol. Chem. 283 (2008) 29266-29272
12. Melmed G.Y., et al. Certolizumab pegol. Nat. Rev. Drug Discov. 7 (2008) 641-642
13. Karagiannis P., et al. Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells. Cancer Immunol. Immunother. 58 (2008) 915-930
14. Dechant M., et al. Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptor. J. Immunol. 179 (2007) 2936-2943
15. Nimmerjahn F., and Ravetch J.V. Fcγ receptors as regulators of immune responses. Nat. Rev. Immunol. 8 (2008) 34-47
16. Nezlin R., and Ghetie V. Interactions of immunoglobulins outside the antigen-combining site. Adv. Immunol. 82 (2004) 155-215
17. Basta M. Ambivalent effect of immunoglobulins on the complement system: activation versus inhibition. Mol. Immunol. 45 (2008) 4073-4079
18. Kibe T., et al. Glycosylation and placental transport of immunoglobulin G. J. Clin. Biochem. Nutr. 21 (1996) 57-63
19. Ghirlando R., et al. Glycosylation of human IgG-Fc: influences on structure revealed by differential scanning micro-calorimetry. Immunol. Lett. 68 (1999) 47-52
20. Krapp S., et al. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J. Mol. Biol. 325 (2003) 979-989
21. Yamaguchi Y., et al. Glycoform-dependent conformational alteration of the Fc region of human immunoglobulin G1 as revealed by NMR spectroscopy. Biochim. Biophys. Acta 1760 (2006) 693-700
22. Umana P., et al. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat. Biotechnol. 17 (1999) 176-180
23. Davies J., et al. Expression of GTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies of altered glycoforms leads to an increase in ADCC thro' higher affinity for FcRIII. Biotechnol. Bioeng. 74 (2001) 288-294
24. Shields R.L., et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcγ RIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277 (2002) 26733-26740
25. Shinkawa T., et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 278 (2003) 3466-3473
26. Ferrara C., et al. Modulation of therapeutic antibody effector functions by glycosylation engineering: Influence of Golgi enzyme localization domain and co-expression of heterologous β1, 4-N-acetylglucosaminyltransferase III and Golgi α-mannosidase II. Biotechnol. Bioeng. 93 (2006) 851-861
27. Shibata-Koyama M., et al. The N-linked oligosaccharide at Fcγ RIIIa Asn-45: an inhibitory element for high Fcγ RIIIa binding affinity to IgG glycoforms lacking core fucosylation. Glycobiology 19 (2009) 126-134
28. Deisenhofer J. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-Å resolution. Biochemistry 20 (1981) 2361-2370
29. Sondermann P., et al. The 3.2-A crystal structure of the human IgG1 Fc fragment-FcγRIII complex. Nature 406 (2000) 267-273
30. Radaev S. The structure of human type III Fcγ receptor in complex with Fc. J. Biol. Chem. 276 (2001) 16469-16477
31. Congy-Jolivet N., et al. Recombinant therapeutic monoclonal antibodies: mechanisms of action in relation to structural and functional duality. Crit. Rev. Oncol. Hematol. 64 (2007) 226-233
32. Suzuki E., et al. A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients. Clin. Cancer Res. 13 (2007) 1875-1882
33. Peipp M., et al. Effector mechanisms of therapeutic antibodies against ErbB receptors. Curr. Opin. Immunol. 20 (2008) 436-443
34. Friedländer E., et al. ErbB-directed immunotherapy: antibodies in current practice and promising new agents. Immunol. Lett. 116 (2008) 126-140
35. Schmiedel J., et al. Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. Cancer Cell 13 (2008) 365-373
36. Wang S.Y., and Weiner G. Complement and cellular cytotoxicity in antibody therapy of cancer. Expert Opin. Biol. Ther. 8 (2008) 759-768
37. Roopenian D.C., and Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7 (2007) 715-725
38. Harris R.J. Heterogeneity of recombinant antibodies: linking structure to function. Dev. Biol. (Basel) 122 (2005) 117-127
39. Yan L., et al. Antibody-based therapy for solid tumors. Cancer J. 14 (2008) 178-183
40. Presta L.G. Molecular engineering and design of therapeutic antibodies. Curr. Opin. Immunol. 20 (2008) 460-470
41. Jones A.J., et al. Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys. Glycobiology 17 (2007) 529-540
42. Keck R., et al. Characterization of a complex glycoprotein whose variable metabolic clearance in humans is dependent on terminal N-acetylglucosamine content. Biologicals 36 (2008) 49-60
43. Spiekermann G.M., et al. Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung. J. Exp. Med. 196 (2002) 303-310
44. Bitonti A.J., et al. Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 9763-9768
45. Hamilton S.R., et al. Humanization of yeast to produce complex terminally sialylated glycoproteins. Science 313 (2006) 1441-1443
46. Yamane-Ohnuki N., et al. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol. Bioeng. 87 (2004) 614-622
47. Cox K.M., et al. Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor. Nat. Biotechnol. 24 (2006) 1591-1597
48. Nechansky A., et al. Compensation of endogenous IgG mediated inhibition of antibody-dependent cellular cytotoxicity by glyco-engineering of therapeutic antibodies. Mol. Immunol. 44 (2007) 1815-1817
49. Walsh G., and Jefferis R. Post-translational modifications in the context of therapeutic proteins. Nat. Biotechnol. 24 (2006) 1241-1252
50. Simmons L.C., et al. Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies. J. Immunol. Methods 263 (2002) 133-147
51. Guerry P., and Szymanski C.M. Campylobacter sugars sticking out. Trends Microbiol. 16 (2008) 428-435
52. Wacker M., et al. Substrate specificity of bacterial oligosaccharyltransferase suggests a common transfer mechanism for the bacterial and eukaryotic systems. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 7088-7093
53. Qian J., et al. Structural characterization of N-linked oligosaccharides on monoclonal antibody Cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion. Anal. Biochem. 364 (2007) 8-18
54. Macher B.A., and Galili U. The Galα1,3Galß1,4GlcNAc-R (α-Gal) epitope: a carbohydrate of unique evolution and clinical relevance. Biochim. Biophys. Acta 1780 (2008) 75-88
55. Chung C.H., et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose. N. Engl. J. Med. 358 (2008) 1109-1117
56. Ashford D.A., et al. Site specific glycosylation of recombinant rat and human soluble CD4 variants expressed in CHO cells. J. Biol. Chem. 268 (1993) 3260-3267